https://charts.traderzeitung.de/phases/US05479K1060 string(1387) "{"isin":"US05479K1060","name":"Elutia Inc","stock_id_xnas":15155017,"stock_id_xnys":null,"generated_at":"2026-09-24 01:31:00","days":[{"date":"2026-09-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.855,"close_at":"2026-09-18 21:48:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.86,"close_at":"2026-09-21 21:55:00","complete":true,"perf_pct":0.5848},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":0.825,"close_at":"2026-09-22 18:41:00","complete":true,"perf_pct":-4.0698},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"

Elutia Aktie News & Nachrichten

[WKN: A2QD87 | Symbol: ELUT]

Realtimekurs

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Elutia gefunden werden.

Elutia Nachrichtenticker öffnen

MT Newswires 16.07.2026 23:59 Uhr

Elutia vereinbart Verkauf von SimpliDerm für bis zu 11 Millionen US-Dollar

05:58 PM EDT, 07/16/2026 (MT Newswires) -- Elutia (ELUT) teilte am Donnerstag mit, eine endgültige Vereinbarung zum Verkauf seines SimpliDerm-Geschäft